Inadequate health insurance coverage: A major factor in premature discontinuation of subcutaneous immunotherapy for allergic rhinitis

Ear, Nose and Throat Journal

Volumn 90, Issue 4, 2011, Pages 170-173

  Vaswani, Ravi ^a,b,c   Liu, Yi Chun Carol ^a,b,c   Parikh, Leena ^a,b,c   Vaswani, Surender ^a,b,c  

^a Allergy and Asthma Clinical Center   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Howard County General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

ADULT; ALLERGIC RHINITIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; TREATMENT WITHDRAWAL; DESENSITIZATION; ECONOMICS; HAY FEVER; INSURANCE; PERENNIAL RHINITIS;

ADULT; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 79955640385     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556131109000408     Document Type: Article

References (12)

1. Fornadley JA, Corey JP, Osguthorpe DJ, et al. Allergic rhinitis: Clinical practice guideline. Committee on Practice Standards, American Academy of Otolaryngic Allergy. Otolaryngol Head Neck Surg 1996; 115(1): 115-22.
2. Creticos PS. Immunotherapy with allergens. JAMA 1992; 268(20): 2834-9.
3. Bush RK, Huftel M, Busse W. Selection of patients (for immunotherapy).In: Lockey RF, Bukantz SC, eds. Allergen Immunotherapy. New York:Marcel Decker; 1991:25-49.
4. Burton MJ, Krouse JH, Rosenfeld RM. Extracts from The Cochrane Library: Allergen injection immunotherapy for seasonal allergic rhinitis(review). Otolaryngol Head Neck Surg 2007; 136(4): 511-14.
5. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007; 136(6 SUPPL): S107-24.
6. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999; 82(3): 281-6.
7. Tinkelman D, Smith F, Cole WQ III, Silk HJ. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995; 74(3): 241-6.
8. Senna G, Ridolo E, Calderon M, et al. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9(6): 544-8.
9. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17(1): 37-52.
10. Bernstein JA. Cost-benefit analysis for allergen immunotherapy. Immunol Allergy Clin North Am 2000; 20(3): 593-607.
11. Incorvaia C, Agostinis F, Amoroso S, et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 2007; 39 Spec No: 17-20.
12. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: A large scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010; 104(1): 79-85.